Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple test could forecast kidney disease progression

NCT ID NCT07754019

Knowledge-focused Sponsor: Bezmialem Vakif University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This observational study explores whether levels of a protein called soluble CD163 in blood or urine can reflect how active IgA nephropathy is and how it might progress. Researchers will compare these levels among people with IgA nephropathy, those with a similar kidney condition (FSGS), and healthy controls. They will also track kidney function and protein in the urine over time to see if CD163 levels predict outcomes. The goal is to find a noninvasive biomarker that could help monitor the disease without repeated biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If soluble CD163 proves reliable, it could become a simple blood or urine test to gauge kidney inflammation and forecast outcomes, reducing the need for repeated biopsies.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. The marker may not be specific enough or may not outperform existing tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 87 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older followed at Bezmialem Vakif University with biopsy-proven primary IgA nephropathy or primary focal segmental glomerulosclerosis, together with age- and sex-matched healthy controls without known chronic disease and with normal kidney function. Clinical, laboratory, histopathologic, biomarker, treatment, and follow-up data will be collected according to the approved observational study protocol.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age 18 years or older * Biopsy-proven primary IgA nephropathy or primary focal segmental glomerulosclerosis * Stable kidney function with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m² * Availability of serum and urine samples for soluble CD163 measurement * Availability of relevant demographic, clinical, laboratory, histopathologic, and follow-up data * For the healthy control group: age- and sex-matched individuals without known chronic disease and with normal kidney function * Written informed consent Exclusion Criteria: * \- Secondary IgA nephropathy or secondary focal segmental glomerulosclerosis * Active infection * Acute kidney injury * End-stage kidney disease or ongoing dialysis treatment * Estimated glomerular filtration rate below 15 mL/min/1.73 m² * Recent use of corticosteroids or immunosuppressive therapy * Pregnancy * Active malignancy or history of malignancy * Inadequately stored or unavailable serum and/or urine samples * Missing essential clinical, laboratory, histopathologic, or follow-up data * Absence of written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy

Contacts and locations

Locations

  • Bezmialem Vakif University Health Application and Research Center

    Istanbul, 34093, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.